Explore el sustrato
Search everything we hold — entities, source-backed facts, the conclusions we’re drawing, and the sources behind them. Type a topic, not just a claim. How we source →
21 items across the substrate for “drug discovery”
What we're concluding
7AI Infrastructure Colonizes Drug Discovery: NVIDIA and Foundation Models Reshape Biotech R&D
A wave of AI platform launches and big-pharma partnerships signals that AI-native drug discovery infrastructure—led by NVIDIA's BioNeMo ecosystem and a proliferation of biological foundation models—is crossing from experimental to operational. Traditional pharma is responding by outsourcing cell therapy and discovery workloads to AI-native partners (Novo Nordisk licensing Parkinson's program to Cellular Intelligence, closing its internal unit) rather than building in-house, while strong NVO earnings and a 25% monthly stock run reflect market confidence in the GLP-1/AI thesis. FDA Fast Track for a Parkinson's cell therapy program adds regulatory tailwind to the broader cell and gene therapy vertical.
AI Infrastructure Reshapes Drug Discovery as Pharma Bets Big on Platform Biology
NVIDIA has emerged as the central AI infrastructure layer for biotech, anchoring partnerships with Lilly and Thermo Fisher while its BioNeMo platform underpins a wave of specialized foundation models from companies like Terray Therapeutics and Apheris. Simultaneously, traditional pharma is restructuring R&D around AI — Novo Nordisk's decision to close its internal cell therapy unit while licensing Parkinson's assets to AI-native Cellular Intelligence exemplifies a broader shift toward externalized, platform-driven development. A concurrent burst of AI biotech platform launches (Boltz, Owkin, Basecamp EDEN, Edison Kosmos, Natera) signals the stack is maturing from research tools into production-grade drug discovery infrastructure, validated by strong investor conviction in leading names like Novo Nordisk.
AI Foundation Models Become the New Infrastructure Layer for Drug Discovery
A wave of AI-native platforms and foundation models (NVIDIA BioNeMo, MindWalk's HYFT/ReefIQ, Basecamp's EDEN, Edison's Kosmos, Owkin's OwkinZero, Boltz Lab) is being built out across pharma and biotech R&D, anchored by NVIDIA's hardware partnerships with Thermo Fisher and Lilly and reinforced by MindWalk's move to patent-protect its biological data representation layer. Financial strength at Novo Nordisk (accelerating stock gains, solid Q1 earnings) is coinciding with a strategic pivot away from owning cell therapy manufacturing in-house toward licensing it out to AI-driven specialists like Cellular Intelligence, suggesting capital and R&D focus are rotating toward AI-native platforms rather than traditional biotech infrastructure.
AI Foundation Models Become Biotech's New Infrastructure Layer
A wave of AI-native biological foundation model platforms (NVIDIA BioNeMo, MindWalk's HYFT, Basecamp Research's EDEN, Boltz Lab, Owkin's OwkinZero, Edison Scientific's Kosmos) is emerging as core infrastructure for drug discovery, backed by deep partnerships between chipmakers/AI labs and pharma incumbents (NVIDIA-Thermo Fisher, NVIDIA-Lilly, Tetrascience-Thermo Fisher). Novo Nordisk's strong Q1 earnings and stock rally alongside its decision to shutter its internal cell therapy unit and license a Parkinson's program to AI-native Cellular Intelligence signals a broader pharma pivot from in-house R&D toward outsourcing to specialized AI biotech platforms.
NVIDIA's BioNeMo Ecosystem and AI-Native Biotech Platforms Reshape Pharma R&D
NVIDIA is establishing BioNeMo as core infrastructure for AI-driven drug discovery, cementing partnerships with Thermo Fisher and Lilly for autonomous labs while third parties (Terray Therapeutics, Apheris) ship models on the platform. In parallel, a wave of independent AI foundation-model launches (Boltz Lab, Owkin OwkinZero, Edison Scientific Kosmos, Basecamp Research EDEN, Natera) signals rapid proliferation of AI-native biotech tooling, with Novo Nordisk's pivot to licensing its Parkinson's cell therapy to the AI-driven Cellular Intelligence platform (after shuttering its internal cell therapy unit) exemplifying Big Pharma's shift toward external AI partnerships, all against a backdrop of strong Novo Nordisk earnings and stock performance.
AI Foundation Models Go Bio-Native: Chipmakers, Pharma, and Startups Race to Own the Drug-Discovery Stack
Starting in January 2026, NVIDIA's BioNeMo platform anchored a wave of lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, catalyzing a broader surge of bio-native AI platform launches (MindWalk's HYFT/ReefIQ, Natera, Boltz Lab, Owkin, Edison Scientific) through mid-2026, with MindWalk now moving to patent its underlying biological data representation. In parallel, established pharma is restructuring around this shift: Novo Nordisk closed its internal cell therapy unit and licensed the program out to the AI-native Cellular Intelligence, even as its stock rallied nearly 25% in 30 days on strong Q1 earnings — signaling investor confidence that AI-driven drug discovery infrastructure, not in-house R&D, is where value is consolidating.
AI Infrastructure Goes Native to Drug Discovery: Platforms, Patents, and Pharma Partnerships Converge
A wave of AI infrastructure — NVIDIA's BioNeMo platform, MindWalk's HYFT bio-representation patents, and new foundation-model platforms from Boltz Lab, Owkin, Edison Scientific, and Natera — is being built directly into drug discovery and biotech R&D workflows, with major pharma (Lilly, Thermo Fisher, Novo Nordisk) and specialized biotechs (Terray Therapeutics, Apheris) as early adopters and co-developers. Novo Nordisk's strong Q1 2026 results and stock surge, alongside its restructuring of internal cell therapy work into external AI-platform licensing (Cellular Intelligence), signal that AI-native drug discovery is shifting from experimental tooling to a core commercial and competitive strategy for big pharma.
Datos con fuente
6drug_approvals: 17 drugssources differ
drug_approvals: 46 novel_drugs (Q4 2025)
drug_approvals: 50 novel_drugs (Q4 2024)
Sources we've traced
8AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica
Stellora.AI Advances Quantum Flow to Support Healthcare, Drug Discovery, and Disease Research